Krystal Biotech, Inc. KRYS Free cash flow margin
Free cash flow margin at other companies
Other financials
Where this comes from
Calculated from Krystal Biotech, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s free cash flow margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s free cash flow margin?
- Krystal Biotech, Inc. (KRYS) reported free cash flow margin of 56.9% in Q1 2026.
- How has Krystal Biotech, Inc.'s free cash flow margin changed year-over-year?
- Krystal Biotech, Inc.'s free cash flow margin increased by 40.9% year-over-year, from 40.4% to 56.9%.
- What is the long-term trend for Krystal Biotech, Inc.'s free cash flow margin?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s free cash flow margin has grown at a -50.5% compound annual growth rate (CAGR), from -198.4% to 48.5%.
- What does free cash flow margin mean?
- How much real, spendable cash each sales dollar generates after reinvestment.
- How do you interpret free cash flow margin?
- A high and rising FCF margin is the hallmark of a cash-generative business. Persistent gaps between net margin and FCF margin warrant a look at working capital or capital intensity.
- How does free cash flow margin compare across companies?
- Strong cross-company quality signal; capital-light compounders post structurally higher FCF margins than asset-heavy peers.